Corporate / M&A

Healthcare / Life Sciences

IP / IT

Competition

Employment and Executive Compensation

On December 13, 2022, Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that it has entered into a definitive agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump, an insulin delivery solution.
The consideration includes a previous strategic investment of CHF 8.0 m, an upfront cash payment of CHF 62.4 m, and additional contingent earnout payments of up to CHF 129.6 m, in aggregate, payable upon the achievement of certain milestones. The transaction is subject to the satisfaction of customary closing conditions and is expected to close in January 2023.
Homburger, who also advised AMF Medical on its previous financing rounds, acts as transaction counsel to AMF Medical SA and its shareholders. The Homburger team comprises Andreas Müller, Margrit Marti and Léonard Aeschlimann Perales (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin and Joel Fink (both IP / IT; Healthcare / Life Sciences), Stefan Oesterhelt, Kevin Müller and Philippe Weber (all Tax), Richard Stäuber and Allegra Arnold (both Competition; Healthcare / Life Sciences), and Marc Bircher and Sebastian Wyler (both Employment and Executive Compensation).

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Capital Markets

Financing and Investment Products

Vectivio

On October 13, 2022, VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the release of its interim data from the first five of nine patients in its ongoing Phase 2 STARS Nutrition clinical trial, the pricing of a USD 125 m underwritten offering of ordinary shares, and an amendment to its financing agreement with Kreos Capital VI (UK) Limited, including the right to receive additional warrants under certain conditions.
The underwritten offering consists of 16,700,000 ordinary shares at an offering price of USD 7.50 per share. Investors include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion&#8217;s Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors.
The Homburger team includes partner Andreas Müller, associates Margrit Marti and Oliver Kneubühl, and junior associate Julien Di Sabato (all Capital Markets; Corporate / M&amp;A), partner Jürg Frick, associates Simone Gloor and Stefan Bindschedler, and junior associate Thibault Sieber (all Financing and Investment Products), partner Stefan Oesterhelt and associate Kevin Müller (both Tax), and partner Luca Dal Molin (IP / IT).

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

On June 14, VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the pricing of a follow-on public offering of ordinary shares in the United States, raising gross proceeds of USD 30 m. In addition, VectivBio has agreed to a concurrent private placement of ordinary shares for gross proceeds of approximately USD 20 m.
The Homburger team includes partner Andreas Müller and lead associate Margrit Marti (both Capital Markets; Corporate / M&amp;A), associates Kevin Hubacher, Angela Oppliger and Oliver Kneubühl (all Corporate / M&amp;A), and partner Stefan Oesterhelt and associate Kevin Müller (both Tax).

Kevin
Müller

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Homburger advises VectivBio on its follow-on public offering and concurrent private placement

Berücksichtigung der Berufskosten bei COVID-19-bedingtem Homeoffice: Kantonale Praxen im Überblick

Join the Team

Kevin Müller

Career

Languages

Teams

KevinMüller

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Homburger advises VectivBio on its follow-on public offering and concurrent private placement

Berücksichtigung der Berufskosten bei COVID-19-bedingtem Homeoffice: Kantonale Praxen im Überblick

Join the Team

Kevin Müller

Career

Languages

Teams

Kevin
Müller